Anti-obesity drugs: a review about their effects and their safety

Bibliography

• National Institutes of Health. Clinical Guidelines on the identification, evaluation, and treatment of overweight and obesity in adults–the evidence report. Obes Res 1998;6(2):51S-209S
   PubMedGoogle Scholar
• Fried M, Hainer V, Basdevant A, Interdisciplinary European guidelines on surgery for severe obesity. Rozhl Chir 2008;87:468-76
   PubMedGoogle Scholar
• Pagotto U, Vanuzzo D, Vicennati V, Pasquali RG. Pharmacological therapy of obesity. G Ital Cardiol (Rome) 2008;9:83S-93S
   PubMedGoogle Scholar
• Marovic D. Elevated body mass index fatty liver. Srp Arh Celok Lek 2008;136:122-5
   PubMed Web of Science ®Google Scholar
• Lavie CJ, Artham SM, Milani RV, Ventura HO. The obesity paradox: impact of obesity on the prevalence prognosis of cardiovascular diseases. Postgrad Med 2008;120:34-41
   PubMed Web of Science ®Google Scholar
• Guh DP, Zhang W, Bansback N, The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009;9:88
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Nutrition principles and recommendations in diabetes. Diabetes Care 2004;27(S1):36-46
   Google Scholar
• American Diabetes Association. Physical activity/exercise and diabetes. Diabetes Care 2004;27(S1):58-62
   Google Scholar
• Lee M, Aronne LJ. Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction. Am J Cardiol 2007;99:68B-79B
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. Obes Res 1998;6(2):51S-209S
   PubMedGoogle Scholar
• WIN-Publication-Prescription Medications for the Treatment of Obesity. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). National Institutes of Health; Bethesda; 2009
   Google Scholar
• Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007;369:71-7
   PubMed Web of Science ®Google Scholar
• Soyka M. Rimonabant and depression. Pharmacopsychiatry 2008;41:204-5
   PubMed Web of Science ®Google Scholar
• Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004;164:994-1003
   PubMed Web of Science ®Google Scholar
• James WPT, Caterson ID, Coutinho W, for the SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010;363:905-17
   PubMed Web of Science ®Google Scholar
• European Medicines Agency recommends suspension of marketing authorisations for sibutramine. Press release of the European Medicines Agency, London, January 21,2010. Available from: http://www.ema.europa.eu/pdfs/human/referral/sibutramine/3940810en.pdf
   Google Scholar
• Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm228830.htm
   Google Scholar
• Colombo G, Agabio R, Diaz G, Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 1998;63:113-17
   Web of Science ®Google Scholar
• Soyka M. Rimonabant and depression. Pharmacopsychiatry 2008;41:204-5
   PubMed Web of Science ®Google Scholar
• Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500014774.pdf
   Google Scholar
• Greenway FL, Caruso MK. Safety of obesity drugs. Expert Opin Drug Saf 2005;4(6):1083-95
   PubMedGoogle Scholar
• Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309:1286-91
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, Assessing the quality of randomized controlled trials: is blinding necessary? Control Clin Trials 1996;17:1-12
   PubMedGoogle Scholar
• Colman E. Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann Intern Med 2005;143(5):380-5
   PubMed Web of Science ®Google Scholar
• Bays HE, Rodbard RW, Schorr AB, Gonzalez-Campoy JM. Adiposopathy: treating pathogenic adipose tissue to reduce cardiovascular disease risk. Curr Treat Options Cardiovasc Med 2007;9(4):259-71
   PubMedGoogle Scholar
• Douglas A, Douglas JG, Robertson CE, Munro JF. Plasma phentermine levels, weight loss and side-effects. Int J Obes 1983;7(6):591-5
   PubMed Web of Science ®Google Scholar
• Munro JF. Clinical aspects of the treatment of obesity by drugs: a review. Int J Obes 1979;3(2):171-80
   PubMed Web of Science ®Google Scholar
• Pasquali R, Casimirri F, Melchionda N, Effects of chronic administration of ephedrine during very-low-calorie diets on energy expenditure, protein metabolism and hormone levels in obese subjects. Clin Sci (Lond) 1992;82(1):85-92
   PubMed Web of Science ®Google Scholar
• Lorello C, Goldfield GS, Doucet E. Methylphenidate hydrochloride increases energy expenditure in healthy adults. Obesity (Silver Spring) 2008;16(2):470-2
   PubMed Web of Science ®Google Scholar
• Coyne TC. Phentermine – resin or salt – there are differences. Arch Intern Med 1997;157(20):2381-2
   PubMed Web of Science ®Google Scholar
• Curfman GD. Diet pills redux. N Engl J Med 1997;337:629-30
   PubMed Web of Science ®Google Scholar
• Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004;164:994-1003
   PubMed Web of Science ®Google Scholar
• Leung WY, Thomas GN, Chan JC, Tomlinson B. Weight management and current options in pharmacotherapy: orlistat and sibutramine. Clin Ther 2003;25(1):58-80
   PubMed Web of Science ®Google Scholar
• Wong NN, Cheng-Lai A. Orlistat. Heart Dis 2000;2:174-81
   PubMedGoogle Scholar
• Zhi J, Moore R, Kanitra L, Mulligan TE. Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects. J Clin Pharmacol 2002;42:1011-19
   PubMed Web of Science ®Google Scholar
• MacWalter RS, Fraser HW, Armstrong KM. Orlistat enhances warfarin effect. Ann Pharmacother 2003;37:510-12
   PubMed Web of Science ®Google Scholar
• Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213038.htm
   Google Scholar
• Colombo G, Agabio R, Diaz G, Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 1998;63:113-17
   Web of Science ®Google Scholar
• Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005;8:585-9
   PubMed Web of Science ®Google Scholar
• Janero DR, Makriyannis A. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin Emerg Drugs 2009;14:43-65
   PubMed Web of Science ®Google Scholar
• Christensen R, Kristensen PK, Bartels EM, Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007;370:1706-13
   PubMed Web of Science ®Google Scholar
• Kang JG, Park CY, Kang JH, Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity. Diabetes Obes Metab 2010;12(10):876-82
   PubMed Web of Science ®Google Scholar
• Kim KK, Cho HJ, Kang HC, Effects on weight reduction and safety of short-term phentermine administration in Korean obese people. Yonsei Med J 2006;47(5):614-25
   PubMed Web of Science ®Google Scholar
• Weintraub M, Hasday JD, Mushlin AI, Lockwood DH. A double-blind clinical trial in weight control use of fenfluramine and phentermine alone and in combination. Arch Intern Med 1984;144(6):1143-8
   PubMed Web of Science ®Google Scholar
• Valle-Jones JC, Brodie NH, O'Hara H, A comparative study of phentermine and diethylpropion in the treatment of obese patients in general practice. Pharmatherapeutica 1983;3(5):300-4
   PubMedGoogle Scholar
• Weintraub M, Sundaresan PR, Madan M, Long-term weight control study I (weeks 0 to 34) the enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther 1992;51:586-94
   PubMed Web of Science ®Google Scholar
• Derosa G, D'Angelo A, Salvadeo SA, Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone. Metabolism 2008;57(11):1552-7
   PubMed Web of Science ®Google Scholar
• Derosa G, Cicero AF, Murdolo G, Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes Obes Metab 2005;7(1):7-55
   Google Scholar
• Derosa G, Cicero AF, Murdolo G, Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. Diabetes Nutr Metab 2004;17(4):222-9
   PubMedGoogle Scholar
• Derosa G, Maffioli P, Ferrari I, Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients. J Pharm Pharm Sci 2010;13(3):378-90
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Ferrari I, Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients. J Clin Pharm Ther 2011;36(5):592-601
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Salvadeo SA, Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients. Metabolism 2011;60(3):421-9
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Salvadeo SA, Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients. Intern Med 2010;49(16):1717-25
   PubMed Web of Science ®Google Scholar
• Sari R, Eray E, Ozdem S, Comparison of the effects of sibutramine versus sibutramine plus metformin in obese women. Clin Exp Med 2010;10(3):179-84
   PubMed Web of Science ®Google Scholar
• Van Gaal LF, Caterson ID, Coutinho W, SCOUT Investigators. Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial. Diabetes Obes Metab 2010;12:26-34
   PubMed Web of Science ®Google Scholar
• Weeke P, Andersson C, Fosbøl EL, The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in period. BMC Endocr Disord 2010;10:3
   PubMedGoogle Scholar
• Caterson I, Coutinho W, Finer N, SCOUT Investigators. Early response to sibutramine in patients not meeting current label criteria: preliminary analysis of SCOUT lead-in period. Obesity (Silver Spring) 2010;18:987-94
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Salvadeo SAT, Comparison of orlistat treatment and placebo in obese type 2 diabetic patients. Expert Opin Pharmacother 2010;11(12):1971-82
   PubMed Web of Science ®Google Scholar
• Derosa G, Cicero AFG, D'Angelo A, Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes. J Clin Pharm Ther 2012;37(2):187-95
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Ferrari I, Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients. Endocr J 2010;57(9):777-86
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Ferrari I, Comparison between orlistat plus L-carnitine and orlistat alone on inflammation parameters in obese diabetic patients. Fundam Clin Pharmacol 2011;25(5):642-51
   PubMed Web of Science ®Google Scholar
• Pekala J, Patkowska-Sokoła B, Bodkowski R, L-carnitine - metabolic functions and meaning in humans life. Curr Drug Metab 2011;12(7):667-78
   PubMed Web of Science ®Google Scholar
• Valsamakis G, McTernan PG, Chetty R, Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism 2004;53:430-4
   PubMed Web of Science ®Google Scholar
• Kelley DE, Bray GA, Pi-Sunyer FX, Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2002;25(6):1033-41
   PubMed Web of Science ®Google Scholar
• Jacob S, Rabbia M, Meier MK, Hauptman J. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes Metab 2009;11(4):361-71
   PubMed Web of Science ®Google Scholar
• Hollander PA, Elbein SC, Hirsch IB, Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998;21:1288-94
   PubMed Web of Science ®Google Scholar
• Kunos G, Osei-Hyiaman D, Liu J, Endocannabinoids and the control of energy homeostasis. J Biol Chem 2008;283:33021-5
   PubMed Web of Science ®Google Scholar
• Onaivi ES. An endocannabinoid hypothesis of drug reward and drug addiction. Ann NY Acad Sci 2008;1139:412-21
   PubMed Web of Science ®Google Scholar
• Walker JM, Huang SM, Strangman NM, Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci USA 1999;96:12198-203
   PubMed Web of Science ®Google Scholar
• Van Gaal LF, Rissanen AM, Scheen AJ, Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-97
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer FX, Aronne LJ, Heshmati HM, RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761-75
   PubMed Web of Science ®Google Scholar
• Despres JP, Golay A, Sjostrom L; Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-34
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Hollander P, Chevalier S, Iranmanesh A; SERENADE Study Group. SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes. Diabetes Care 2008;31(11):2169-76
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Salvadeo SA, Exenatide versus glibenclamide in patients with diabetes. Diabetes Technol Ther 2010;12(3):233-40
   PubMed Web of Science ®Google Scholar
• Derosa G, Putignano P, Bossi AC, Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. Eur J Pharmacol 2011;666(1-3):251-6
   PubMed Web of Science ®Google Scholar
• Vilsbøll T, Christensen M, Junker AE, Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012;344:d7771
   PubMed Web of Science ®Google Scholar
• Weigle DS. Pharmacological therapy of obesity: past, present, and future. J Clin Endocrinol Metab 2003;88(6):2462-9
   PubMed Web of Science ®Google Scholar
• Larsen MH, Rosenbrock H, Sams-Dodd F, Mikkelsen JD. Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine re-uptake inhibitor tesofensine. Eur J Pharmacol 2007;555:115-21
   PubMed Web of Science ®Google Scholar
• Astrup A, Meier DH, Mikkelsen BO, Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease. Obesity (Silver Spring) 2008;16(6):1363-9
   PubMed Web of Science ®Google Scholar
• Kaplan LM. Pharmacological therapies for obesity. Gastroenterology Clinics of North America 2005;34(1):91-104
   PubMed Web of Science ®Google Scholar
• Vivus, Inc. VIVUS Announces Positive Results From Two Phase 3 Studies: Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities: Results of EQUIP and CONQUER Phase 3 Studies Exceed FDA Benchmarks for Obesity Treatments, Demonstrate Positive Safety Profile. Available from: http://ir.vivus.com/releasedetail.cfm?ReleaseID=407933
   Google Scholar
• Gadde KM, Yonish GM, Foust MS, Wagner HR. Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. J Clin Psychiatry 2007;68(8):1226-9
   PubMed Web of Science ®Google Scholar
• Kojima M, Hosoda H, Date Y, Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402(6762):656-60
   PubMed Web of Science ®Google Scholar
• Wren AM, Seal LJ, Cohen MA, Ghrelin enhances appetite and increases food intake in humans. Clin Endocrinol Metab 2001;86(12):5992
   Google Scholar
• Beck B, Richy S, Stricker-Krongrad A. Feeding response to ghrelin agonist and antagonist in lean and obese zucker rats. Life Sci 2004;76(4):473-8
   PubMed Web of Science ®Google Scholar
• Katsuura G, Asakawa A, Inui A. Roles of pancreatic polypeptide in regulation of food intake. Peptides 2002;23(2):323-9
   PubMed Web of Science ®Google Scholar
• Batterham RL, Le Roux CW, Cohen MA, Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 2003;88(8):3989-92
   PubMed Web of Science ®Google Scholar
• Hollander P, Maggs DG, Ruggles JA, Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res 2004;12(4):661-8
   PubMedGoogle Scholar
• Druce MR, Bloom SR. Oxyntomodulin: a novel potential treatment for obesity. Treat Endocrinol 2006;5(5):265-72
   PubMedGoogle Scholar
• Keller U. From obesity to diabetes. Int J Vitam Nutr Res 2006;76:172-7
   PubMed Web of Science ®Google Scholar
• Astrup A, Rossner S. Lessons from obesity management programmes: greater initial weight loss improves long-term maintenance. Obes Rev 2000;1:17-19
   PubMedGoogle Scholar
• Meigs JB, Singer DE, Sullivan LM, Metabolic control and prevalent cardiovascular disease in non-insulin-dependent diabetes mellitus (NIDDM): the NIDDM Patient Outcome Research Team. Am J Med 1997;102:38-47
   PubMed Web of Science ®Google Scholar
• Available from: www.rxabbott.com/pdf/meridia.pdf
   Google Scholar